These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 10473031)

  • 1. A method for estimating and testing area under the curve in serial sacrifice, batch, and complete data designs.
    Holder DJ; Hsuan F; Dixit R; Soper K
    J Biopharm Stat; 1999 Aug; 9(3):451-64. PubMed ID: 10473031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of AUC from 0 to Infinity in Serial Sacrifice Designs.
    Wolfsegger MJ; Jaki T
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):757-66. PubMed ID: 16328101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new mathematical approach for the estimation of the AUC and its variability under different experimental designs in preclinical studies.
    Navarro-Fontestad C; González-Álvarez I; Fernández-Teruel C; Bermejo M; Casabó VG
    Pharm Stat; 2012; 11(1):14-23. PubMed ID: 21268234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved designs for dose escalation studies using pharmacokinetic measurements.
    Piantadosi S; Liu G
    Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity.
    Bieler GS; Williams RL
    Biometrics; 1993 Sep; 49(3):793-801. PubMed ID: 8241374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients in the stable posttransplant period.
    Mathew BS; Fleming DH; Annapandian VM; Prasanna S; Prasanna CG; Chandy SJ; John GT
    Ther Drug Monit; 2010 Apr; 32(2):136-40. PubMed ID: 20110849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the encounter rate variance in distance sampling.
    Fewster RM; Buckland ST; Burnham KP; Borchers DL; Jupp PE; Laake JL; Thomas L
    Biometrics; 2009 Mar; 65(1):225-36. PubMed ID: 18363772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing bioequivalence in serial sacrifice designs.
    Wolfsegger MJ
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):103-13. PubMed ID: 17053981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A measure of tumorigenic potency incorporating dose-response shape.
    Meier KL; Bailer AJ; Portier CJ
    Biometrics; 1993 Sep; 49(3):917-26. PubMed ID: 8241378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence review for drug interchangeability.
    Chow SC; Shao J
    J Biopharm Stat; 1999 Aug; 9(3):485-97. PubMed ID: 10473033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing animal subsets in toxicokinetic studies: comparison of non-linear mixed effects modelling with non-compartmental methods.
    Hing JP; Woolfrey SG; Greenslade D; Wright PM
    J Appl Toxicol; 2002; 22(6):437-43. PubMed ID: 12424748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Power and sample size estimation for the Wilcoxon rank sum test with application to comparisons of C statistics from alternative prediction models.
    Rosner B; Glynn RJ
    Biometrics; 2009 Mar; 65(1):188-97. PubMed ID: 18510654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomization tests for assessing the equality of area under curves for studies using destructive sampling.
    Bailer AJ; Ruberg SJ
    J Appl Toxicol; 1996; 16(5):391-5. PubMed ID: 8889790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
    Slob W; Moerbeek M; Rauniomaa E; Piersma AH
    Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-stage method of estimation for general linear growth curve models.
    Stukel TA; Demidenko E
    Biometrics; 1997 Jun; 53(2):720-8. PubMed ID: 9192460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies.
    Cheung BW; Cartier LL; Russlie HQ; Sawchuk RJ
    Fundam Clin Pharmacol; 2005 Jun; 19(3):347-54. PubMed ID: 15910659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.
    Figurski MJ; Nawrocki A; Pescovitz MD; Bouw R; Shaw LM
    Ther Drug Monit; 2008 Aug; 30(4):445-55. PubMed ID: 18641543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal sampling times in bioequivalence tests.
    Kong FH; Gonin R
    J Biopharm Stat; 2000 Feb; 10(1):31-44. PubMed ID: 10709799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.